...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Dopamine D(3) receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum.
【24h】

Dopamine D(3) receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum.

机译:多巴胺D(3)受体调节通过毒蕈碱受体从伏隔大鼠核切片中诱发的多巴胺释放,而不是纹状体。

获取原文
获取原文并翻译 | 示例
           

摘要

It is not clear whether dopamine D(3) receptor contributes to the regional difference in dopamine antagonist-induced increase in the evoked dopamine release from the nucleus accumbens and striatum. We investigated the regional differences in augmentation of electrically evoked dopamine release induced by preferential dopamine D(2) or D(3) receptor antagonists from slices of the rat striatum and nucleus accumbens. Haloperidol, a preferential dopamine D(2) receptor antagonist, enhanced the evoked dopamine release from both the striatum and nucleus accumbens. Preferential dopamine D(3) antagonists, cis-(+)-(1S, 2R)-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin HCl [(+)-UH232] and 5,6-dimethoxy-2-(di-n-propylamine)indan (U-99194A) resulted in a greater increase in the evoked dopamine released from the nucleus accumbens compared with that from the striatum. Moreover, U-99194A attenuated the quinpirole-induced reduction of evoked dopamine release from the nucleus accumbens but not from the striatum. When slices were superfused with pirenzepine, a muscarinic receptor antagonist, the increase in the evoked dopamine release by (+)-UH232 or U-99194A was reduced in the nucleus accumbens to the same level as that in the striatum. Our results indicate that the preferential D(3) receptor antagonists-induced increase in evoked dopamine release is probably mediated by the cholinergic system in the nucleus accumbens, which contains more postsynaptic dopamine D(3) receptors than the striatum.
机译:目前尚不清楚多巴胺D(3)受体是否促成多巴胺拮抗剂引起的伏隔核和纹状体诱发的多巴胺释放的区域差异。我们调查了由大鼠纹状体和伏隔核切片中的优先多巴胺D(2)或D(3)受体拮抗剂诱导的诱发的多巴胺释放的区域差异。氟哌啶醇,一种优先的多巴胺D(2)受体拮抗剂,增强了纹状体和伏隔核诱发的多巴胺释放。首选多巴胺D(3)拮抗剂,顺式(+)-(1S,2R)-5-甲氧基-1-甲基-2-(二-正丙基氨基)四氢萘HCl [(+)-UH232]和5,6与纹状体相比,-二甲氧基-2-(二-正丙胺)茚满(U-99194A)导致伏隔核释放的诱发多巴胺的增加更大。此外,U-99194A减弱了喹吡罗诱导的伏隔多巴胺从伏隔核(而不是纹状体)释放引起的多巴胺释放的减少。当切片与毒蕈碱受体拮抗剂吡仑西平融合时,伏隔核中由(+)-UH232或U-99194A引起的多巴胺释放的增加减少到与纹状体相同的水平。我们的结果表明,优先D(3)受体拮抗剂引起的诱发多巴胺释放增加可能是由伏隔核中的胆碱能系统介导的,该系统包含比纹状体更多的突触后多巴胺D(3)受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号